Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb, 12-week, five-arm, global, double-blind, placebo-controlled study of modified-release dipyridamole/prednisolone in patients with moderate to severe rheumatoid arthritis: SYNERGY.

Trial Profile

Phase IIb, 12-week, five-arm, global, double-blind, placebo-controlled study of modified-release dipyridamole/prednisolone in patients with moderate to severe rheumatoid arthritis: SYNERGY.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dipyridamole/prednisolone (Primary) ; Dipyridamole; Prednisolone; Prednisone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Zalicus
  • Most Recent Events

    • 13 Sep 2012 Primary endpoint 'significant difference between dipyridamole and placebo in disease-activity-score' has been met, according to a Zalicus media release.
    • 13 Sep 2012 Secondary endpoint `significant difference between dipyridamole/prednisolone and prednisolone in disease activity score' not met, according to a Zalicus media release.
    • 10 Sep 2012 Status of parent trial changed from active, no longer recruiting to completed, according to ClinicalTrials.gov (NCT01369745).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top